Clinical trials: sponsored by Anhui Provincial Hospital
Autoimmune Diseases
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases.
- Trial name
- LCAR1901 (NCT07121777)
- Testing
- Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Leukemia
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
CD7 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. Approximately 10-30% of cute myeloid leukemia(AML) patients exhibit CD7 expression, particularly in early myeloid progenitor cell-derived…
- Trial name
- NCT07120607
- Testing
- CD7 CAR-γδT cell（QH106）, Fludarabine (FLU), Cyclophosphamide (CTX)
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Immune Thrombocytopenia (ITP)
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia.
- Trial name
- LCAR1901 (NCT06973356)
- Testing
- Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Artificial Intelligence, Lung Nodule
Artificial Intelligence for Pathology Diagnosis and Prognosis Prediction of Lung Nodule Using Smartphone Photos
The current study aims to develop and validate a deep learning signature for diagnosing pathology and predicting prognosis of lung nodule using smartphone photos of resected tumor specimens.
- Trial name
- NCT07098884
- Testing
- AI model
- Where
- 3 sites in China
- Volunteers
- 600 people
- Sponsor
- Anhui Provincial Hospital
Chemotherapy-induced Neutropenia
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
The objective of this real world study is to confirm the efficacy and saftey of Telpegfilgrastim injection for the prevention of chemotherapy-induced Neutropenia in Patients With Malignant solid tumor.
- Trial name
- NCT07096479
- Testing
- Telpegfilgrastim Injection
- Where
- 2 sites in China
- Volunteers
- 318 people
- Sponsor
- Anhui Provincial Hospital
Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
- Conditions
- Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL)
- Trial name
- NCT07085559
- Testing
- Metabolically Armed BCMA CAR-T cells.
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Anhui Provincial Hospital
Cervical Cancer
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
Based on the trend that the incidence and mortality of cervical carcinoma among female cancers worldwide are increasing year by year, the investigators aim to develop a multi-epitope therapeutic vaccine capable of simultaneously…
- Trial name
- NCT07077980
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Anhui Provincial Hospital
Lung Cancer, Esophageal Cancer
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
At present, the treatment methods for recurrent cancers are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent lung cancer/ esophageal cancer / cervical cancer, but the clinical…
- Conditions
- Lung Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT06232083
- Testing
- PLDR+Cardunizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Autoimmune Diseases
CAR-T Cells Therapy for Patients With Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
- Trial name
- ECAR01 (NCT07052565)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Carcinoma
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is definitive concurrent chemoradiotherapy (CCRT).
- Trial name
- NCT07034118
- Testing
- Proton radiotherapy, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Anhui Provincial Hospital
Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM)
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma.
- Trial name
- ECAR01 (NCT06961669)
- Testing
- Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Alzheimer's Disease Diagnosis
Clinical Evaluation of Blood-Based Assays for Rapid Detection of Aβ Pathology in Alzheimer's Disease
Background: Blood-based biomarkers show promise in predicting Alzheimer's disease (AD) pathology and progression; however, inconsistencies in detection standards hinder clinical application.
- Trial name
- CLEAR AD (NCT06889896)
- Testing
- After Blood samples collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Cancer
Tumor Immunity and Cancer Recurrence Prediction Model
The purpose of this observational study is to understand the predictive effect of the laboratory-developed TIMES scoring system on the recurrence status of cancer patients who have undergone surgical tumor resection.
- Trial name
- NCT06855290
- Volunteers
- 300 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer
The goal of this observational study is to compare 5.0T and 3.0T biparametric magnetic resonance imaging in the diagnosis of prostate cancer.
- Trial name
- 5TbpMRI (NCT06612047)
- Testing
- Prostate biopsy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
A Diagnostic Prediction Model for Prostate Cancer in Patients With PI-RADS Score 3
The goal of this observational study is to construct a predictive model for improving the diagnostic accuracy in patients with PI-RADS score of 3.
- Trial name
- NCT06507462
- Testing
- prostate biopsy
- Where
- 3 sites in China
- Volunteers
- 460 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer
The goal of this study is to evaluate the diagnostic value of different ADC values (incuding ADCmin, ADCmean, ADCratio and ADCrange) of bpMRI in patients with PI-RADS 3-5.
- Trial name
- NCT06737588
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Carcinoma
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma…
- Trial name
- NCT05937438
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital
B Lymphoblastic Leukemia/Lymphoma
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
This study is designed to explore the safety and efficacy for patients with relapsed and/or refractory B-cell lymphoblastic leukemia.
- Trial name
- NCT06307600
- Testing
- RD06-03 cell injection
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Intrahepatic Cholangiocarcinoma
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
Evaluating the efficacy and safety of treatment with Tislelizumab in combination with S-1 in patients with high-risk recurrent intrahepatic cholangiocarcinoma after radical surgery
- Trial name
- NCT06664021
- Testing
- Tislelizumab combined with S-1
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Cancer, Non Small Cell Lung Cancer
A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy
For the recurrent and metastatic tumors after first-line treatment (such as lung cancer, esophageal cancer and cervical cancer), the risk of conventional fractionated secondary radiotherapy is high because the tumor is close to…
- Conditions
- Esophageal Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06760676
- Testing
- Pulsed low dose rate radiotherapy (PLDR), Alpaloritovorelli antibodies
- Volunteers
- 90 people
- Sponsor
- Anhui Provincial Hospital